

silenceworks

BENITEC'S PROGRESS IN SILENCE

Market Snapshot

Market Data

ASX Code:BLT
 OTC Code BTEBY
 Share Price: AUD 1.15
 Market Cap: AUD 132,133,612
 52 week high/low AUD 2.38/0.325
 Shares on issue: 114,898,793
 * Converted to post consolidation pricing

In this issue

- ▶ Benitec doses first patient in 'first in man' clinical trial
- ▶ Maxim and Shaw initiate coverage with 'BUY'
- ▶ Benitec rises YTD 780% plus patent update from Lodge
- ▶ Calimmune to proceed with ddRNAi-based HIV trial
- ▶ Benitec opens laboratory in Northern California
- ▶ Benitec expands Australian team
- ▶ Benitec's CEO on ABC TV

RNA INTERFERENCE
siRNA
 and
ddRNAi



See Benitec's ddRNAi explained



Benitec doses first patient in 'first in man' clinical trial

On May 29, Benitec [announced](#) that the first patient had been dosed in the clinical trial of TT034, a ddRNAi based drug designed to treat – and potentially cure – Hepatitis C via a single injection. The commencement of the trial was covered by several major news outlets, including the Herald Sun, Adelaide Advertiser, [CentreWatch](#), BRW and news.com. [ASX Announcement](#).



Benitec rises YTD 780% plus patent update from Lodge

On July 1, Biotech Daily, which reports daily on ASX listed Biotech companies, reported Benitec's year to date rise at 780%. [Full report](#). On May 27, [Lodge Partners](#) released a flash note update with further background to the European Patent Office's opposition ruling to patent EP 155531 and the licencing of EP 1444346. The report concluded that the latter strengthened Benitec's near-term IP position. [Full report](#).



Maxim and Shaw initiate coverage 'BUY' recommendation

In June, analysts at [Maxim Group](#) (USA) and [Shaw Stockbroking](#) (Australia) initiated coverage on Benitec, rating the stock as a 'buy'. The reports refer to Benitec's ddRNAi platform 'as an undiscovered gem in the world of RNAi technology' with Shaw noting 'the technology is potentially worth 10s of \$bns.' Please follow links to the individual reports.



Calimmune to proceed with ddRNAi-based HIV trial

On June 26, Calimmune, a privately-owned, US-based licensee of Benitec, [received approval](#) to proceed with the second patient cohort in its Phase I/II clinical trial of Cal-1, a treatment and potential cure for HIV based on ddRNAi. This follows review of trial data from the first cohort by the Data Safety Monitoring Board (DSMB), which confirmed that none of the four participants experienced any serious adverse events or side effects from the therapy. [ASX Announcement](#).



Benitec opens laboratory in Northern California

Dr David Suhy (Benitec's Senior Vice President R&D) and Dr Michael Graham (CSO) will manage a new laboratory secured by Benitec in North California. The facility is a key step in moving Benitec from outsourced laboratory operations to in-house control of research and development. Two scientists who worked with Dr Suhy on the TT-034 program at Tacere Therapeutics will work in the laboratory, providing continuity of ddRNAi expertise. US publication [Genome Web](#) covered the US lab establishment, following Benitec's [General Meeting presentation](#) release.



Terrie-Anne Cock Sakura Holloway

Benitec expands Australian team

Benitec recently expanded its Australian team by two. Terrie-Anne Cock joins the Sydney team, she is managing Benitec's preclinical programs including lung cancer and Hepatitis B. Sakura Holloway joins as in-house Patent Attorney. Having worked most recently at CSIRO managing its RNAi IP estate, Sakura brings a wealth of patent expertise to the on-going stewardship of Benitec's key IP assets.



Benitec's CEO on ABC's 'The Business'

CEO and MD Dr Peter French was again interviewed on ABC TV's 'The Business' program. Discussion included Calimmune's gaining of approval to proceed to clinical trial (see above), its implications for Benitec and more. [Full interview](#).